TY  - JOUR
AU  - Lugtenburg, Pieternella
AU  - Avivi, Irit
AU  - Berenschot, Henriette
AU  - Ilhan, Osman
AU  - Marolleau, Jean Pierre
AU  - Nagler, Arnon
AU  - Rueda, Antonio
AU  - Tani, Monica
AU  - Turgut, Mehmet
AU  - Osborne, Stuart
AU  - Smith, Rodney
AU  - Pfreundschuh, Michael
PY  - 2017
DO  - 10.3324/haematol.2017.173583
UR  - https://hdl.handle.net/10668/26747
T2  - Haematologica
AB  - Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce treatment burden. MabEase...
LA  - en
KW  - Administration, Intravenous
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cyclophosphamide
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Infusions, Subcutaneous
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Patient Satisfaction
KW  - Prednisone
KW  - Proportional Hazards Models
KW  - Rituximab
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Vincristine
TI  - Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
TY  - research article
VL  - 102
ER  -